Compare HLF & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | PSNL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 939.1M | 872.1M |
| IPO Year | N/A | 2019 |
| Metric | HLF | PSNL |
|---|---|---|
| Price | $14.92 | $8.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $14.00 | $10.71 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.95 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $4,961,900,000.00 | $69,103,000.00 |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $3.52 | $20.33 |
| P/E Ratio | $4.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.04 | $2.83 |
| 52 Week High | $15.00 | $11.40 |
| Indicator | HLF | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 78.28 | 44.25 |
| Support Level | $11.61 | $9.34 |
| Resistance Level | $13.35 | $9.85 |
| Average True Range (ATR) | 0.67 | 0.70 |
| MACD | 0.21 | -0.20 |
| Stochastic Oscillator | 90.74 | 5.19 |
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.